BidaskClub lowered shares of Insmed (NASDAQ:INSM) from a hold rating to a sell rating in a report issued on Tuesday morning.

Several other analysts also recently issued reports on the company. Zacks Investment Research downgraded Insmed from a buy rating to a hold rating in a research note on Thursday, January 18th. Credit Suisse Group started coverage on Insmed in a research note on Wednesday, January 17th. They issued a neutral rating and a $31.00 price target on the stock. Robert W. Baird reaffirmed a positive rating and issued a $42.00 target price (up previously from $32.00) on shares of Insmed in a research report on Thursday, January 4th. ValuEngine raised Insmed from a sell rating to a hold rating in a research report on Friday, February 2nd. Finally, HC Wainwright reaffirmed a buy rating and issued a $35.00 target price on shares of Insmed in a research report on Thursday, January 4th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Insmed has a consensus rating of Hold and an average price target of $36.90.

How to Become a New Pot Stock Millionaire

Shares of Insmed (NASDAQ INSM) opened at $23.57 on Tuesday. Insmed has a 12 month low of $11.49 and a 12 month high of $33.94. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.72 and a current ratio of 8.72.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Friday, February 23rd. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.18). equities analysts anticipate that Insmed will post -3.64 EPS for the current year.

Several large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in shares of Insmed by 11.7% in the fourth quarter. BlackRock Inc. now owns 7,830,604 shares of the biopharmaceutical company’s stock valued at $244,159,000 after acquiring an additional 817,915 shares during the last quarter. Palo Alto Investors LLC increased its position in shares of Insmed by 3.8% in the fourth quarter. Palo Alto Investors LLC now owns 6,404,586 shares of the biopharmaceutical company’s stock valued at $199,695,000 after acquiring an additional 232,770 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Insmed by 140.2% in the third quarter. Janus Henderson Group PLC now owns 3,960,748 shares of the biopharmaceutical company’s stock valued at $123,615,000 after acquiring an additional 2,312,045 shares during the last quarter. Redmile Group LLC increased its position in shares of Insmed by 12.9% in the fourth quarter. Redmile Group LLC now owns 2,249,262 shares of the biopharmaceutical company’s stock valued at $70,132,000 after acquiring an additional 257,616 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Insmed by 2.9% in the fourth quarter. Geode Capital Management LLC now owns 691,982 shares of the biopharmaceutical company’s stock valued at $21,575,000 after acquiring an additional 19,710 shares during the last quarter. 99.08% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “BidaskClub Lowers Insmed (INSM) to Sell” was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2018/03/23/bidaskclub-lowers-insmed-insm-to-sell.html.

About Insmed

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.